This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (29)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pulmonary Diseases, Other  • Liver/ Biliary Tract/ Pancreatic Diseases  • Renal Diseases, Other  • Oncology  • Venous Thromboembolism  • Alert me on articles by topic

Helen K. Chew, MD; Theodore Wun, MD; Danielle Harvey, PhD; Hong Zhou, PhD; Richard H. White, MD

Arch Intern Med. 2006;166:458-464.

Background:  The incidence of venous thromboembolism after diagnosis of specific cancers and the effect of thromboembolism on survival are not well defined.

Methods:  The California Cancer Registry was linked to the California Patient Discharge Data Set to determine the incidence of venous thromboembolism among cancer cases diagnosed between 1993 and 1995. The incidence and timing of thromboembolism within 1 and 2 years of cancer diagnosis and the risk factors associated with thromboembolism and death were determined.

Results:  Among 235 149 cancer cases, 3775 (1.6%) were diagnosed with venous thromboembolism within 2 years, 463 (12%) at the time cancer was diagnosed and 3312 (88%) subsequently. In risk-adjusted models, metastatic disease at the time of diagnosis was the strongest predictor of thromboembolism. Expressed as events per 100 patient-years, the highest incidence of thromboembolism occurred during the first year of follow-up among cases with metastatic-stage pancreatic (20.0), stomach (10.7), bladder (7.9), uterine (6.4), renal (6.0), and lung (5.0) cancer. Adjusting for age, race, and stage, diagnosis of thromboembolism was a significant predictor of decreased survival during the first year for all cancer types (hazard ratios, 1.6-4.2; P<.01).

Conclusions:  The incidence of venous thromboembolism varied with cancer type and was highest among patients initially diagnosed with metastatic-stage disease. The incidence rate of thromboembolism decreased over time. Diagnosis of thromboembolism during the first year of follow-up was a significant predictor of death for most cancer types and stages analyzed. For some types of cancer, the incidence of thromboembolism was sufficiently high to warrant prospective clinical trials of primary thromboprophylaxis.

Author Affiliations: Divisions of Hematology/Oncology (Drs Chew and Wun) and General Medicine (Drs Zhou and White), Department of Internal Medicine, and Department of Public Health Sciences (Dr Harvey), University of California, Davis, Sacramento; and Section of Hematology and Oncology, Veterans Affairs Northern California Health Care System, Sacramento (Dr Wun).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention
Gerber et al.
Blood 2008;112:504-510.
ABSTRACT | FULL TEXT  

Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Geerts et al.
Chest 2008;133:381S-453S.
ABSTRACT | FULL TEXT  

Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana et al.
Blood 2008;111:4902-4907.
ABSTRACT | FULL TEXT  

Use of Thromboprophylaxis in Palliative Care Patients: A Survey Among Experts in Palliative Care, Oncology, Intensive Care, and Anticoagulation
Kierner et al.
AM J HOSP PALLIAT CARE 2008;25:127-131.
ABSTRACT  

The Risk of Venous Thromboembolism in Patients with Cancer
Khorana et al.
Am Soc Clin Oncol Ed Book 2008;2008:240-248.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Lyman et al.
JCO 2007;25:5490-5505.
ABSTRACT | FULL TEXT  

The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients
Khorana
The Oncologist 2007;12:1361-1370.
ABSTRACT | FULL TEXT  

Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
Mandala et al.
Ann Oncol 2007;18:1660-1665.
ABSTRACT | FULL TEXT  

Lupus Anticoagulant Activity as a Thrombosis Risk Factor in Lung Adenocarcinoma Patients
DE MEIS et al.
Ann. N. Y. Acad. Sci. 2007;1107:51-55.
ABSTRACT | FULL TEXT  

Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients
Chew et al.
JCO 2007;25:70-76.
ABSTRACT | FULL TEXT